Literature DB >> 24387978

Reliability of post-chemoradiotherapy F-18-FDG PET/CT for prediction of locoregional failure in human papillomavirus-associated oropharyngeal cancer.

Jeffrey M Vainshtein1, Matthew E Spector2, Matthew H Stenmark3, Carol R Bradford2, Gregory T Wolf2, Francis P Worden4, Douglas B Chepeha2, Jonathan B McHugh5, Thomas Carey2, Ka Kit Wong6, Avraham Eisbruch3.   

Abstract

OBJECTIVES: Although widely adopted, the accuracy of post-chemoradiotherapy (CRT) 18F-fluorodeoxygluocose positron emission tomography/computed tomography (PET/CT) for predicting locoregional failure (LRF) in human papillomavirus-related (HPV+) oropharyngeal cancer (OPC) remains poorly characterized. We assessed the predictive value of 3-month PET/CT response for LRF in this population.
MATERIALS AND METHODS: 101 consecutive patients with stage III-IV HPV+ OPC who underwent definitive CRT with pre-treatment and 3-month post-CRT PET/CT at our institution from 3/2005-3/2011 were included. 3-month PET/CT response was re-classified as complete-response (CR), near-CR, or incomplete-response (<CR) for each the primary site and neck. Accuracy of 3-month PET/CT for predicting local failure (LF) and regional failure (RF) was analyzed.
RESULTS: Among 98 patients with an evaluable primary tumor, LF occurred in 2/67 patients with CR, 0/20 with near-CR, and 1/11 with <CR on 3-month PET/CT. Of 98 node-positive patients, RF occurred in 6/80 with CR, 2/9 with near-CR, and 0/7 with <CR in the neck at 3 months. Sensitivity and positive predictive value (PPV) of 3-month PET/CT response for LF and RF were low (0-33%), despite a high negative predictive value (NPV) (91-98%). SUVmax thresholds or % change did not improve the accuracy of 3-month PET/CT. Use of additional PET/CT surveillance after 3 months in 67 patients accurately detected both LF (96%) and RF (97%).
CONCLUSIONS: In the largest study to-date of PET/CT response assessment in HPV+ OPC, 3-month PET/CT response demonstrated high NPV for LRF, though with disappointing sensitivity and PPV. Subsequent PET/CT surveillance showed potential utility for early detection of LRFs.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Chemoradiotherapy; Human papillomavirus; Metabolic response; PET surveillance; PET/CT

Mesh:

Substances:

Year:  2013        PMID: 24387978      PMCID: PMC4159357          DOI: 10.1016/j.oraloncology.2013.12.003

Source DB:  PubMed          Journal:  Oral Oncol        ISSN: 1368-8375            Impact factor:   5.337


  21 in total

1.  The role of positron emission tomography scans in the management of the N-positive neck in head and neck squamous cell carcinoma after chemoradiotherapy.

Authors:  Victoria S Brkovich; Frank R Miller; Anand B Karnad; David H Hussey; H Stan McGuff; Randal A Otto
Journal:  Laryngoscope       Date:  2006-06       Impact factor: 3.325

2.  Controversies in treatment deintensification of human papillomavirus-associated oropharyngeal carcinomas: should we, how should we, and for whom?

Authors:  Harry Quon; Arlene A Forastiere
Journal:  J Clin Oncol       Date:  2013-01-07       Impact factor: 44.544

3.  Reliability of CT-based tumor volumetry after intraarterial chemotherapy in patients with small carcinoma of the oral cavity and the oropharynx.

Authors:  Stefan Rohde; Adorján F Kovács; Joachim Berkefeld; Bernd Turowski
Journal:  Neuroradiology       Date:  2006-04-12       Impact factor: 2.804

4.  The role of neck dissection after chemoradiotherapy for oropharyngeal cancer with advanced nodal disease.

Authors:  G L Clayman; C J Johnson ; W Morrison; L Ginsberg; S M Lippman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  2001-02

5.  Selective lymph node dissection following hyperfractionated accelerated radio-(chemo-)therapy for advanced head and neck cancer.

Authors:  Thomas Hehr; Johannes Classen; Ulrike Schreck; Stefan Glocker; Assen Koitschev; Michael Bamberg; Wilfried Budach
Journal:  Strahlenther Onkol       Date:  2002-07       Impact factor: 3.621

6.  Clinical utility of 18F-FDG PET/CT in assessing the neck after concurrent chemoradiotherapy for Locoregional advanced head and neck cancer.

Authors:  Seng Chuan Ong; Heiko Schöder; Nancy Y Lee; Snehal G Patel; Diane Carlson; Matthew Fury; David G Pfister; Jatin P Shah; Steven M Larson; Dennis H Kraus
Journal:  J Nucl Med       Date:  2008-03-14       Impact factor: 10.057

7.  Deferring planned neck dissection following chemoradiation for stage IV head and neck cancer: the utility of PET-CT.

Authors:  Jayakar V Nayak; Rohan R Walvekar; Regiane S Andrade; Nicole Daamen; Stephen Y Lai; Athanassios Argiris; Ryan P Smith; Dwight E Heron; Robert L Ferris; Jonas T Johnson; Barton F Branstetter
Journal:  Laryngoscope       Date:  2007-12       Impact factor: 3.325

8.  Necessity for adjuvant neck dissection in setting of concurrent chemoradiation for advanced head-and-neck cancer.

Authors:  David M Brizel; Robert G Prosnitz; Shannon Hunter; Samuel R Fisher; Robert L Clough; Mary Ann Downey; Richard L Scher
Journal:  Int J Radiat Oncol Biol Phys       Date:  2004-04-01       Impact factor: 7.038

9.  Evaluation of prevertebral muscle invasion by squamous cell carcinoma. Can computed tomography replace open neck exploration?

Authors:  P D Righi; D J Kelley; R Ernst; M D Deutsch; M Gaskill-Shipley; K M Wilson; J L Gluckman
Journal:  Arch Otolaryngol Head Neck Surg       Date:  1996-06

Review 10.  A systematic review and meta-analysis of the role of positron emission tomography in the follow up of head and neck squamous cell carcinoma following radiotherapy or chemoradiotherapy.

Authors:  M G Isles; C McConkey; H M Mehanna
Journal:  Clin Otolaryngol       Date:  2008-06       Impact factor: 2.597

View more
  18 in total

1.  (18)F-FDG PET/CT to assess response and guide risk-stratified follow-up after chemoradiotherapy for oropharyngeal squamous cell carcinoma.

Authors:  Thomas Bird; Sally Barrington; Selvam Thavaraj; Jean-Pierre Jeannon; Andrew Lyons; Richard Oakley; Ricard Simo; Mary Lei; Teresa Guerrero Urbano
Journal:  Eur J Nucl Med Mol Imaging       Date:  2015-12-28       Impact factor: 9.236

2.  Assessment of outcomes with delayed (18)F-FDG PET-CT response assessment in head and neck squamous cell carcinoma.

Authors:  F Slevin; M Subesinghe; S Ramasamy; M Sen; A F Scarsbrook; R J D Prestwich
Journal:  Br J Radiol       Date:  2015-06-17       Impact factor: 3.039

3.  Second-look PET-CT following an initial incomplete PET-CT response to (chemo)radiotherapy for head and neck squamous cell carcinoma.

Authors:  Robin J D Prestwich; Moses Arunsingh; Jim Zhong; Karen E Dyker; Sriram Vaidyanathan; Andrew F Scarsbrook
Journal:  Eur Radiol       Date:  2019-08-29       Impact factor: 5.315

Review 4.  Emerging biomarkers in head and neck cancer in the era of genomics.

Authors:  Hyunseok Kang; Ana Kiess; Christine H Chung
Journal:  Nat Rev Clin Oncol       Date:  2014-11-18       Impact factor: 66.675

5.  Matted nodes: High distant-metastasis risk and a potential indication for intensification of systemic therapy in human papillomavirus-related oropharyngeal cancer.

Authors:  Jeffrey M Vainshtein; Matthew E Spector; Mohannad Ibrahim; Carol R Bradford; Gregory T Wolf; Matthew H Stenmark; Francis P Worden; Jonathan B McHugh; Mark E Prince; Thomas Carey; Douglas B Chepeha; Avraham Eisbruch
Journal:  Head Neck       Date:  2015-07-15       Impact factor: 3.147

6.  No benefit for regional control and survival by planned neck dissection in primary irradiated oropharyngeal cancer irrespective of p16 expression.

Authors:  R Maquieira; S K Haerle; G F Huber; A Soltermann; S R Haile; S J Stoeckli; Martina A Broglie
Journal:  Eur Arch Otorhinolaryngol       Date:  2015-06-10       Impact factor: 2.503

7.  Association of Fludeoxyglucose F 18-Labeled Positron Emission Tomography and Computed Tomography With the Detection of Oropharyngeal Cancer Recurrence.

Authors:  Shanmugappiriya Sivarajah; Andre Isaac; Tim Cooper; Han Zhang; Lakshmi Puttagunta; Jonathan Abele; Vincent Biron; Jeffery Harris; Hadi Seikaly; Daniel A O' Connell
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2018-11-01       Impact factor: 6.223

8.  Saliva and plasma quantitative polymerase chain reaction-based detection and surveillance of human papillomavirus-related head and neck cancer.

Authors:  Sun M Ahn; Jason Y K Chan; Zhe Zhang; Hao Wang; Zubair Khan; Justin A Bishop; William Westra; Wayne M Koch; Joseph A Califano
Journal:  JAMA Otolaryngol Head Neck Surg       Date:  2014-09       Impact factor: 6.223

9.  FDG-PET/CT for treatment response assessment in head and neck squamous cell carcinoma: a systematic review and meta-analysis of diagnostic performance.

Authors:  Nils Helsen; Tim Van den Wyngaert; Laurens Carp; Sigrid Stroobants
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-02-24       Impact factor: 9.236

10.  Quantification of 18F-fluorodeoxyglucose uptake to detect residual nodal disease in locally advanced head and neck squamous cell carcinoma after chemoradiotherapy: results from the ECLYPS study.

Authors:  Nils Helsen; Tim Van den Wyngaert; Laurens Carp; Remco De Bree; Olivier M VanderVeken; Frank De Geeter; Alex Maes; Jean-Philippe Cambier; Karoline Spaepen; Michel Martens; Sara Hakim; Laurence Beels; Otto S Hoekstra; Danielle Van den Weyngaert; Sigrid Stroobants; Carl Van Laer; Pol Specenier; Annelies Maes; Philip Debruyne; Isabel Hutsebaut; Joost Van Dinter; Filip Homans; Laurence Goethals; Oliver Lenssen; Kristof Deben
Journal:  Eur J Nucl Med Mol Imaging       Date:  2020-02-10       Impact factor: 9.236

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.